Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate avt06 and reference product eylea® (aflibercept)

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for avt06, alvotech's proposed biosimilar to eylea® (aflibercept).
ALVO Ratings Summary
ALVO Quant Ranking